WCWan-Yu Chen

Wan-Yu Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wan-Yu Chen has a total of 299 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nasopharyngeal Carcinoma in Intensity‐Modulated Radiation Therapy Era: Competing‐Risk Analysis, Recurrence, and Postrecurrence Survival

    by Chun‐Wei Wang, Bing‐Shen Huang, Hsiang‐Kuang Liang, Wan‐Yu Chen

    Background: This study assessed long‐term outcomes in nasopharyngeal carcinoma (NPC) patients treated with modern intensity‐modulated radiation therapy (IMRT), focusing on recurrence patterns and postrecurrence survival (PRS). Methods: A cohort of 1554 NPC patients treated with definitive radiotherapy or concurrent chemoradiotherapy (CCRT) between 2005 and 2019 was analyzed using competing‐risk models. Cumulative incidences of recurrence or death, local recurrence or death, regional recurrence or death, and distant recurrence or death were calculated, with subgroup differences evaluated by Gray's test. PRS was assessed using Kaplan–Meier curves, log‐rank tests, and Cox proportional hazards models. Results: The 3‐, 5‐, and 10‐year cumulative incidences of recurrence or death were 0.143, 0.162, and 0.187. T4 tumors showed poorer local control, and cumulative incidences of distant recurrence or death correlated with N classification. Most recurrences occurred within 2–3 years, with distant recurrences significantly reducing PRS. Conclusion: IMRT provides excellent local‐regional control but requires improvement for T4 tumors and distant recurrences affecting PRS.


  • Open Access

    Knowledge-Based RapidPlan Volumetric Modulated Arc Therapy Model in Nasopharyngeal Carcinoma

    by Szu-Huai Lu, Chun-Wei Wang, Hsiang-Kuang Liang, Chih-Kai Chang, Hao-Ting Lan, Shih-Fan Lai, Bing-Shen Huang, Wan-Yu Chen


  • Vertebral artery sparing volumetric modulated arc therapy in nasopharyngeal carcinoma

    by Szu-Huai Lu, Hao-Ting Lan, Yi-Chun Tsai, Ya-Fang Chen, Shih-Fan Lai, Hsiang-Kuang Liang, Bing-Shen Huang, Wan-Yu Chen, Chun-Wei Wang

  • Open Access

    Effect of extended field‐of‐view approaches on the accuracy of stopping power ratio estimation for single‐energy computed tomography simulators

    by Chang‐Shiun Lin, Yi‐Chun Tsai, Liang‐Hsin Chen, Chun‐Wei Wang, Chia‐Jung Wu, Wan‐Yu Chen, Hsiang‐Kung Liang, Sung‐Hsin Kuo

    Background: Extended field‐of‐view (eFOV) methods have been proposed to generate larger demonstration FOVs for computed tomography (CT) simulators with a limited scanning FOV (sFOV) size in order to ensure accurate dose calculation and patient collision avoidance. Although the efficacy of these strategies has been evaluated for photon applications, the effect of stopping power ratio (SPR) estimation on proton therapy has not been studied. This study investigated the effect of an eFOV approach on the accuracy of SPR to water estimation in homogeneous and heterogeneous phantoms.Materials and Methods: To simulate patient geometries, tissue‐equivalent material (TEM) and customized extension phantoms were used. The TEM phantom supported various rod arrangements through predefined holes. Images were reconstructed to three FOV sizes using a commercial eFOV technique. A single‐energy CT stoichiometric method was used to generate Hounsfield unit (HU) to SPR (HU‐to‐SPR) conversion curves for each FOV. To investigate the effect of rod location in the sFOV and eFOV regions, eight TEM rods were placed at off‐center distances in the homogeneous phantom and scanned individually. Similarly, 16 TEM rods were placed in the heterogeneous TEM phantom and scanned simultaneously.Results: The conversion curves derived from the sFOV and eFOV data were identical. The average SPR differences of soft‐tissue, bone, and lung materials for rods placed at various off‐center locations were 3.3%, 4.8%, and 39.6%, respectively. In the heterogeneous phantom, the difference was within 1.0% in the absence of extension. However, in the presence of extension, the difference increased to 2.8% for all rods, except for lung materials, whose difference was 4.8%.Conclusions: When an eFOV method is used, the SPR variation in phantoms considerably increases for all TEM rods, especially for lung TEM rods. This phenomenon may substantially increase the uncertainty of HU‐to‐SPR conversion. Therefore, image reconstruction with a standard FOV size is recommended.


  • Open Access

    Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion

    by Ching-Hsin Lee, An-Hsin Chen, Sheng-Ping Hung, Cheng-En Hsieh, Jeng-Hwei Tseng, Po-Jui Chen, Jen-Yu Cheng, Joseph Tung-Chieh Chang, Kun-Ming Chan, Shi-Ming Lin, et al.

    Hepatocellular carcinoma (HCC) with bile duct invasion is a rare and notorious subtype of HCC. This study included patients that had unresectable HCC with bile duct invasion and proton beam therapy between November 2015 and February 2021. Twenty patients fit the inclusion criteria. The median tumor size was 6.3 cm. Nine patients (45.0%) had major vascular invasions. All included patients received the radiation dose of 72.6 gray relative biological effectiveness due to the proximity of porta hepatis and tumor. The median follow-up time was 19.9 months. The median overall survival was 19.9 months among deceased patients. The 1-year cumulative local recurrence rates were 5.3%, with only two patients developing in-field failure. The 1-year and 2-year overall survival rates were 79.4% and 53.3%. The 1-year progression-free survival was 58.9%. Four patients developed radiation-induced liver disease. The 1-year cholangitis-free survival was 55.0%. Skin toxicity was the most common acute toxicity and rarely severe. Eight patients developed ≤ grade 3 gastrointestinal ulcers. Proton beam therapy offers desirable survival outcomes for unresectable HCC patients with bile duct invasion. Optimal local tumor control could also be obtained within acceptable toxicities.


  • Open Access

    Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node

    by Wan‐Yu Chen, Ku‐Hao Fang, Chun‐Wei Wang, Chun‐Ta Liao, Tzu‐Chen Yen, Taun‐Jen Fang, Shih‐Fan Lai, Hsiang‐Kuang Liang, Bing‐Shen Huang

    Objective: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1new in this study).Methods: A total of 243 low/intermediate risk pN1new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence‐free survival (LRFS), regional recurrence‐free survival (RRFS), and distant metastasis‐free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone.Results: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5‐year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1new patients.Conclusion: For low/intermediate risk pN1new patients with oral cavity cancer, adjuvant therapy might be omitted.Level of Evidence: 4.


  • Open Access

    Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer

    by Wan-Yu Chen, Tseng-Cheng Chen, Shih-Fan Lai, Tony Hsiang-Kuang Liang, Bing-Shen Huang, Chun-Wei Wang

    Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are limited. This study aimed to compare the treatment outcomes between definitive chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. Ninety-three N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT may achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Caution should be made to avoid overtreatment for this group of patients.


  • Open Access

    Less is Enough: Outcome of Bimodality Definitive Concurrent Chemoradiation does not Differ from that of Trimodality Upfront Neck Dissection Followed by Adjuvant Treatment for >6 cm Bulky Lymph Node (N3) Head and Neck Cancer

    by Wan-Yu Chen, Tseng-Cheng Chen, Shih-Fan Lai, Tony Hsiang-Kuang Liang, Bing-Shen Huang, Chun-Wei Wang

    Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are lacking. This study aimed to compare the treatment outcomes between definitive concurrent chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. 93 N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT can achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Cautions should be made to avoid overtreatment for this group of patients.

  • Open Access

    Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer

    by Wan-Yu Chen, Chen-Tu Wu, Chun-Wei Wang, Keng-Hsueh Lan, Hsiang-Kuang Liang, Bing-Shen Huang, Yih-Leong Chang, Sung-Hsin Kuo, Ann-Lii Cheng

    Our aim was to investigate the prognostic significance of tumor-infiltrating lymphocytes (TILs) in operable tongue cancer patients. The presence of CD3+, CD4+, CD8+, and forkhead box protein P3-positive (FOXP3+) TILs in tumor tissues obtained from 93 patients during surgery was examined using immunohistochemistry. The 3-year overall survival (OS) of patients with a low CD8/FOXP3 ratio was significantly lower than that of patients with a high CD8/FOXP3 ratio (63.8% vs. 87.3%, p = 0.001). Patients with high FOXP3 had a significantly lower 3-year regional recurrence-free survival (RRFS) than did patients with low FOXP3 (49.3% vs. 87.3%, univariate log rank p = 0.000). A low CD4/FOXP3 ratio (68.4% vs. 93.7%, univariate log rank p = 0.002) was significantly unfavorable prognostic factors for 3-year distant metastasis-free survival (DMFS). In addition to clinicopathological characteristics, TIL markers represent prognosticators for clinical outcomes.


  • The extent of edema and tumor synchronous invasion into the subventricular zone and corpus callosum classify outcomes and radiotherapy strategies of glioblastomas

    by Hsiang-Kuang Tony Liang, Wan-Yu Chen, Shih-Fan Lai, Mao-Yuan Su, San-Lin You, Liang-Hsin Chen, Ham-Min Tseng, Chung-Ming Chen, Sung-Hsin Kuo, Wen-Yih Isaac Tseng